- Home
- BXP vs SRPT Comparison
BXP vs SRPT Comparison
Compare BXP & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BXP
- SRPT
- Stock Information
- Founded
- BXP 1970
- SRPT 1980
- Country
- BXP United States
- SRPT United States
- Employees
- BXP N/A
- SRPT N/A
- Industry
- BXP Real Estate Investment Trusts
- SRPT Biotechnology: Pharmaceutical Preparations
- Sector
- BXP Real Estate
- SRPT Health Care
- Exchange
- BXP Nasdaq
- SRPT Nasdaq
- Market Cap
- BXP 11.6B
- SRPT 9.8B
- IPO Year
- BXP 1997
- SRPT 1997
- Fundamental
- Price
- BXP $67.52
- SRPT $70.41
- Analyst Decision
- BXP Buy
- SRPT Buy
- Analyst Count
- BXP 13
- SRPT 21
- Target Price
- BXP $80.85
- SRPT $164.05
- AVG Volume (30 Days)
- BXP 1.5M
- SRPT 2.2M
- Earning Date
- BXP 04-29-2025
- SRPT 04-30-2025
- Dividend Yield
- BXP 5.79%
- SRPT N/A
- EPS Growth
- BXP N/A
- SRPT N/A
- EPS
- BXP 0.09
- SRPT 2.34
- Revenue
- BXP $3,380,319,000.00
- SRPT $1,901,979,000.00
- Revenue This Year
- BXP $1.71
- SRPT $67.83
- Revenue Next Year
- BXP $2.88
- SRPT $25.66
- P/E Ratio
- BXP $834.90
- SRPT $30.11
- Revenue Growth
- BXP 4.45
- SRPT 52.97
- 52 Week Low
- BXP $56.46
- SRPT $69.82
- 52 Week High
- BXP $90.11
- SRPT $173.25
- Technical
- Relative Strength Index (RSI)
- BXP 48.31
- SRPT 27.35
- Support Level
- BXP $67.82
- SRPT $70.91
- Resistance Level
- BXP $69.43
- SRPT $76.67
- Average True Range (ATR)
- BXP 1.73
- SRPT 4.14
- MACD
- BXP 0.29
- SRPT -1.57
- Stochastic Oscillator
- BXP 74.03
- SRPT 1.78
About BXP Boston Properties Inc.
BXP Inc. owns over 180 properties consisting of approximately 53 million rentable square feet of space. The portfolio is dominated by office buildings and is spread across major cities such as New York, Boston, San Francisco, Los Angeles, Seattle, and the Washington, D.C., region. The real estate investment trust also owns limited retail, hotel, and residential properties.
About SRPT Sarepta Therapeutics Inc. (DE)
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.